QQQ   312.04 (+0.10%)
AAPL   156.95 (+4.06%)
MSFT   263.51 (-0.41%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   312.04 (+0.10%)
AAPL   156.95 (+4.06%)
MSFT   263.51 (-0.41%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   312.04 (+0.10%)
AAPL   156.95 (+4.06%)
MSFT   263.51 (-0.41%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   312.04 (+0.10%)
AAPL   156.95 (+4.06%)
MSFT   263.51 (-0.41%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
NASDAQ:CDXC

ChromaDex - CDXC Stock Forecast, Price & News

$2.05
-0.04 (-1.91%)
(As of 02/3/2023 12:00 PM ET)
Add
Compare
Today's Range
$1.99
$2.09
50-Day Range
$1.46
$2.19
52-Week Range
$1.15
$3.16
Volume
214,122 shs
Average Volume
254,310 shs
Market Capitalization
$152.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.40

ChromaDex MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
170.0% Upside
$5.40 Price Target
Short Interest
Bearish
4.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.45mentions of ChromaDex in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.24) to ($0.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

386th out of 1,029 stocks

Medicinals & Botanicals Industry

2nd out of 15 stocks

CDXC stock logo

About ChromaDex (NASDAQ:CDXC) Stock

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Receive CDXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

CDXC Stock News Headlines

ChromaDex (NASDAQ:CDXC) Receives Buy Rating from HC Wainwright
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
ChromaDex Named Brianna Gerber Chief Financial Officer
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Chromadex Corp
See More Headlines
Receive CDXC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ChromaDex and its competitors with MarketBeat's FREE daily newsletter.

CDXC Company Calendar

Last Earnings
11/02/2021
Today
2/03/2023
Next Earnings (Estimated)
3/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CDXC
Employees
115
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.40
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$2.10
Forecasted Upside/Downside
+163.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-27,130,000.00
Pretax Margin
-29.71%

Debt

Sales & Book Value

Annual Sales
$67.45 million
Book Value
$0.46 per share

Miscellaneous

Free Float
65,682,000
Market Cap
$152.66 million
Optionable
Optionable
Beta
1.77

Key Executives

  • Robert N. FriedRobert N. Fried
    Chief Executive Officer & Director
  • Brianna Gerber
    Chief Financial Officer
  • Ryan Dellinger
    Director-Scientific Affairs
  • Fadi Karam
    Chief Marketing Officer
  • Trent Crane
    Regional Vice President-Sales













CDXC Stock - Frequently Asked Questions

Should I buy or sell ChromaDex stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ChromaDex in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CDXC shares.
View CDXC analyst ratings
or view top-rated stocks.

What is ChromaDex's stock price forecast for 2023?

4 brokers have issued 12 month price objectives for ChromaDex's stock. Their CDXC share price forecasts range from $2.10 to $7.00. On average, they expect the company's share price to reach $5.40 in the next twelve months. This suggests a possible upside of 158.4% from the stock's current price.
View analysts price targets for CDXC
or view top-rated stocks among Wall Street analysts.

How have CDXC shares performed in 2023?

ChromaDex's stock was trading at $1.68 on January 1st, 2023. Since then, CDXC shares have increased by 24.4% and is now trading at $2.09.
View the best growth stocks for 2023 here
.

When is ChromaDex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 8th 2023.
View our CDXC earnings forecast
.

How were ChromaDex's earnings last quarter?

ChromaDex Co. (NASDAQ:CDXC) released its earnings results on Tuesday, November, 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.04. The company earned $17.31 million during the quarter, compared to analyst estimates of $17.18 million. ChromaDex had a negative net margin of 29.71% and a negative trailing twelve-month return on equity of 90.73%. During the same quarter in the prior year, the company posted ($0.07) EPS.

What is Robert Fried's approval rating as ChromaDex's CEO?

13 employees have rated ChromaDex Chief Executive Officer Robert Fried on Glassdoor.com. Robert Fried has an approval rating of 38% among the company's employees. This puts Robert Fried in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 46.0% of employees surveyed would recommend working at ChromaDex to a friend.

What other stocks do shareholders of ChromaDex own?
What is ChromaDex's stock symbol?

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

Who are ChromaDex's major shareholders?

ChromaDex's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Cowen Prime Advisors LLC (0.10%), International Assets Investment Management LLC (0.03%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Frank L Jaksch Jr, Hoi Shuen Solina Holly Chau, Kevin M Farr, Robert N Fried and Stephen A Block.
View institutional ownership trends
.

How do I buy shares of ChromaDex?

Shares of CDXC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ChromaDex's stock price today?

One share of CDXC stock can currently be purchased for approximately $2.09.

How much money does ChromaDex make?

ChromaDex (NASDAQ:CDXC) has a market capitalization of $155.64 million and generates $67.45 million in revenue each year. The company earns $-27,130,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis.

How many employees does ChromaDex have?

The company employs 115 workers across the globe.

How can I contact ChromaDex?

ChromaDex's mailing address is 10900 Wilshire Blvd. Suite 650, Los Angeles CA, 90024. The official website for the company is www.chromadex.com. The company can be reached via phone at (310) 388-6706, via email at investorrelations@chromadex.com, or via fax at 949-419-0294.

This page (NASDAQ:CDXC) was last updated on 2/3/2023 by MarketBeat.com Staff